Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorothee Oberdhan

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Kidney International Reports|June 11, 2020
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan FormulationsRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
International Journal of Nephrology and Renovascular Disease|April 21, 2021
Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey StudyMyrlene Sanon Aigbogun, Dorothee Oberdhan, Michael J Doane, et al.
Pharmacoeconomics|March 24, 2019
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease InterventionsPei-Jung Lin, Brittany D'Cruz, Ashley A Leech, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2017
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life InstrumentDorothee Oberdhan, Jason C Cole, Holly B Krasa, et al.
Kidney Medicine|May 1, 2024
Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered RegistryElise Hoover, Vanessa Holliday, Nicole Merullo, et al.
Kidney Medicine|November 10, 2025
Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development Concepts for Autosomal Recessive Polycystic Kidney Disease Against SONG InitiativesBelle Soyfer, Sorin Fedeles, Wendy Ruyle, et al.
Kidney International|August 2, 2013
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney diseaseWendy E Boertien, Esther Meijer, Paul E de Jong, et al.
Kidney International Reports|May 14, 2023
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKDRonald D Perrone, Dorothee Oberdhan, John Ouyang, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 21, 2015
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney FunctionWendy E Boertien, Esther Meijer, Paul E de Jong, et al.
Neurology and Therapy|February 15, 2023
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's DiseaseDana B DiBenedetti, Heather Menne, Russ Paulsen, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Kidney International Reports|June 11, 2020
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan FormulationsRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
International Journal of Nephrology and Renovascular Disease|April 21, 2021
Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey StudyMyrlene Sanon Aigbogun, Dorothee Oberdhan, Michael J Doane, et al.
Pharmacoeconomics|March 24, 2019
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease InterventionsPei-Jung Lin, Brittany D'Cruz, Ashley A Leech, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2017
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life InstrumentDorothee Oberdhan, Jason C Cole, Holly B Krasa, et al.
Kidney Medicine|May 1, 2024
Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered RegistryElise Hoover, Vanessa Holliday, Nicole Merullo, et al.
Kidney Medicine|November 10, 2025
Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development Concepts for Autosomal Recessive Polycystic Kidney Disease Against SONG InitiativesBelle Soyfer, Sorin Fedeles, Wendy Ruyle, et al.
Kidney International|August 2, 2013
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney diseaseWendy E Boertien, Esther Meijer, Paul E de Jong, et al.
Kidney International Reports|May 14, 2023
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKDRonald D Perrone, Dorothee Oberdhan, John Ouyang, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 21, 2015
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney FunctionWendy E Boertien, Esther Meijer, Paul E de Jong, et al.
Neurology and Therapy|February 15, 2023
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's DiseaseDana B DiBenedetti, Heather Menne, Russ Paulsen, et al.
Pageof 4